“it’s been a long time since something was invented that works for this type of disease,” wang said. “it’s really fulfilling to have patients that are looking for other options or basically reasons to have hope. i think this trial as well as the device is one of the more impactful discoveries for glioblastoma in decades.”
the u.s. food and drug administration approved the device for people with glioblastoma, a particularly aggressive form of cancer that can form in the brain or spinal cord, according to the
mayo clinic
.
however, the fda recommends that people use the device only as a supplement to chemotherapy and radiation.
people who used the optune device in addition to “standard” treatment lived an average of 30 to 50 per cent longer than patients who did not have access to the device.
the upcoming trial, called trident, will see half of the patients use the optune device while undergoing chemo, and the other half use the device while receiving doses of radiation treatment approximately 60 to 90 days earlier than what is considered standard for radiation.
“the idea and the hope is that by having the device earlier, and with it working together with radiation and chemotherapy, it can be even more effective than it was proven to be after radiation,” wang said.
patients lived 30 to 50 per cent longer